 Elizabeth Pomfret
Concepts (488)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 118 | 2023 | 695 | 18.000 |
Why?
| | Living Donors | 71 | 2023 | 270 | 13.110 |
Why?
| | Tissue and Organ Procurement | 26 | 2023 | 226 | 5.920 |
Why?
| | Hepatectomy | 23 | 2023 | 118 | 3.570 |
Why?
| | Donor Selection | 15 | 2023 | 65 | 3.300 |
Why?
| | End Stage Liver Disease | 11 | 2023 | 61 | 2.520 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2023 | 210 | 2.250 |
Why?
| | Liver | 40 | 2023 | 1633 | 2.170 |
Why?
| | Patient Selection | 13 | 2023 | 629 | 2.070 |
Why?
| | Liver Neoplasms | 10 | 2023 | 504 | 1.950 |
Why?
| | Kidney Transplantation | 12 | 2023 | 538 | 1.910 |
Why?
| | Postoperative Complications | 24 | 2023 | 2122 | 1.710 |
Why?
| | Organ Transplantation | 8 | 2023 | 159 | 1.560 |
Why?
| | Tissue Donors | 9 | 2024 | 314 | 1.480 |
Why?
| | Liver Cirrhosis | 7 | 2020 | 227 | 1.420 |
Why?
| | Waiting Lists | 15 | 2023 | 206 | 1.290 |
Why?
| | Tissue and Organ Harvesting | 9 | 2013 | 62 | 1.180 |
Why?
| | Graft Survival | 17 | 2023 | 443 | 1.160 |
Why?
| | Humans | 156 | 2024 | 114043 | 1.070 |
Why?
| | Perfusion | 2 | 2024 | 147 | 1.060 |
Why?
| | Laparoscopy | 3 | 2023 | 395 | 1.050 |
Why?
| | Fatty Liver | 5 | 2023 | 209 | 1.000 |
Why?
| | Hepatitis C, Chronic | 5 | 2022 | 150 | 0.970 |
Why?
| | Liver Diseases | 5 | 2023 | 254 | 0.930 |
Why?
| | Consensus Development Conferences as Topic | 2 | 2020 | 28 | 0.810 |
Why?
| | Graft Rejection | 11 | 2020 | 511 | 0.790 |
Why?
| | Robotic Surgical Procedures | 1 | 2023 | 86 | 0.760 |
Why?
| | Liver Failure | 7 | 2016 | 73 | 0.740 |
Why?
| | Frailty | 1 | 2023 | 113 | 0.700 |
Why?
| | Pain, Postoperative | 3 | 2016 | 190 | 0.700 |
Why?
| | Surgeons | 1 | 2024 | 236 | 0.680 |
Why?
| | Portal Vein | 4 | 2017 | 75 | 0.670 |
Why?
| | United States | 29 | 2023 | 12137 | 0.670 |
Why?
| | Resource Allocation | 4 | 2013 | 37 | 0.630 |
Why?
| | Consensus | 7 | 2024 | 532 | 0.610 |
Why?
| | Immunosuppressive Agents | 6 | 2018 | 641 | 0.610 |
Why?
| | Adult | 61 | 2023 | 30375 | 0.570 |
Why?
| | Hepatic Veins | 5 | 2016 | 29 | 0.550 |
Why?
| | Thrombelastography | 6 | 2023 | 129 | 0.550 |
Why?
| | Healthcare Disparities | 5 | 2023 | 479 | 0.540 |
Why?
| | Treatment Outcome | 29 | 2023 | 9049 | 0.540 |
Why?
| | Female | 72 | 2023 | 59325 | 0.530 |
Why?
| | Male | 74 | 2023 | 55396 | 0.530 |
Why?
| | Antiviral Agents | 4 | 2022 | 642 | 0.530 |
Why?
| | Middle Aged | 56 | 2022 | 26605 | 0.510 |
Why?
| | Venous Thrombosis | 1 | 2017 | 141 | 0.510 |
Why?
| | Blood Coagulation Disorders | 4 | 2022 | 154 | 0.510 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 244 | 0.500 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2017 | 21 | 0.500 |
Why?
| | Biopsy | 9 | 2020 | 1024 | 0.490 |
Why?
| | Transplantation, Homologous | 7 | 2020 | 377 | 0.480 |
Why?
| | Retrospective Studies | 29 | 2023 | 12521 | 0.470 |
Why?
| | Sirolimus | 1 | 2016 | 181 | 0.470 |
Why?
| | Kidney | 6 | 2023 | 1182 | 0.470 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 850 | 0.440 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 204 | 0.440 |
Why?
| | Biliary Tract Diseases | 2 | 2010 | 32 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2272 | 0.430 |
Why?
| | Periodicals as Topic | 1 | 2015 | 180 | 0.420 |
Why?
| | Hepacivirus | 7 | 2022 | 228 | 0.410 |
Why?
| | Diphtheria Toxin | 3 | 2022 | 51 | 0.400 |
Why?
| | Societies, Medical | 2 | 2015 | 655 | 0.400 |
Why?
| | Kidney Failure, Chronic | 3 | 2023 | 489 | 0.400 |
Why?
| | Interleukin-2 | 3 | 2023 | 413 | 0.390 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 98 | 0.390 |
Why?
| | Immunotoxins | 2 | 2023 | 33 | 0.380 |
Why?
| | Hepatitis C | 5 | 2022 | 218 | 0.380 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 40 | 0.380 |
Why?
| | Transplant Recipients | 6 | 2023 | 136 | 0.360 |
Why?
| | Allografts | 3 | 2023 | 121 | 0.350 |
Why?
| | Survival Rate | 12 | 2020 | 1638 | 0.350 |
Why?
| | Patient Safety | 1 | 2012 | 273 | 0.330 |
Why?
| | Quality of Life | 7 | 2020 | 2343 | 0.330 |
Why?
| | Blood Coagulation | 5 | 2023 | 200 | 0.320 |
Why?
| | Directed Tissue Donation | 1 | 2008 | 4 | 0.320 |
Why?
| | Biliary Tract | 1 | 2008 | 16 | 0.320 |
Why?
| | Bioethical Issues | 1 | 2008 | 8 | 0.320 |
Why?
| | Liver Regeneration | 3 | 2003 | 29 | 0.310 |
Why?
| | Software | 2 | 2012 | 527 | 0.310 |
Why?
| | Vascular Surgical Procedures | 1 | 2011 | 260 | 0.310 |
Why?
| | Interpersonal Relations | 1 | 2011 | 338 | 0.310 |
Why?
| | Severity of Illness Index | 8 | 2023 | 2537 | 0.310 |
Why?
| | Risk Factors | 15 | 2023 | 8614 | 0.300 |
Why?
| | Adolescent | 20 | 2020 | 17800 | 0.290 |
Why?
| | Transplants | 2 | 2022 | 36 | 0.280 |
Why?
| | Tacrolimus | 3 | 2020 | 134 | 0.280 |
Why?
| | Fibrinolysis | 3 | 2023 | 126 | 0.270 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2006 | 8 | 0.270 |
Why?
| | Time Factors | 14 | 2021 | 6077 | 0.260 |
Why?
| | Transplantation Immunology | 1 | 2006 | 30 | 0.260 |
Why?
| | Young Adult | 10 | 2021 | 10444 | 0.260 |
Why?
| | Insurance, Life | 1 | 2005 | 2 | 0.250 |
Why?
| | Critical Care | 4 | 2024 | 472 | 0.250 |
Why?
| | Registries | 4 | 2022 | 1764 | 0.250 |
Why?
| | Decision Making | 1 | 2011 | 760 | 0.250 |
Why?
| | International Cooperation | 2 | 2016 | 169 | 0.240 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1381 | 0.240 |
Why?
| | Health Care Rationing | 3 | 2013 | 45 | 0.240 |
Why?
| | Skin Neoplasms | 2 | 2023 | 754 | 0.230 |
Why?
| | Intestines | 2 | 2007 | 325 | 0.230 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 459 | 0.230 |
Why?
| | Length of Stay | 3 | 2023 | 957 | 0.220 |
Why?
| | Solitary Kidney | 1 | 2023 | 6 | 0.220 |
Why?
| | Risk Assessment | 9 | 2022 | 2958 | 0.220 |
Why?
| | Aged | 24 | 2021 | 18969 | 0.220 |
Why?
| | Follow-Up Studies | 10 | 2020 | 4392 | 0.220 |
Why?
| | Sezary Syndrome | 1 | 2023 | 43 | 0.220 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 1168 | 0.220 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 60 | 0.210 |
Why?
| | Body Temperature | 1 | 2023 | 208 | 0.210 |
Why?
| | Operative Time | 1 | 2023 | 106 | 0.210 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 29 | 0.210 |
Why?
| | Thrombosis | 3 | 2022 | 295 | 0.200 |
Why?
| | Death | 3 | 2023 | 106 | 0.200 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2023 | 61 | 0.200 |
Why?
| | Prospective Studies | 11 | 2020 | 6195 | 0.190 |
Why?
| | Bile Ducts | 2 | 2022 | 68 | 0.190 |
Why?
| | Sodium | 1 | 2022 | 184 | 0.190 |
Why?
| | Massachusetts | 2 | 2012 | 134 | 0.190 |
Why?
| | Informed Consent | 2 | 2016 | 158 | 0.190 |
Why?
| | Antibiotic Prophylaxis | 2 | 2020 | 95 | 0.190 |
Why?
| | Physicians | 2 | 2010 | 765 | 0.190 |
Why?
| | Predictive Value of Tests | 5 | 2020 | 1791 | 0.190 |
Why?
| | Evidence-Based Medicine | 3 | 2016 | 662 | 0.190 |
Why?
| | Temperature | 1 | 2023 | 564 | 0.180 |
Why?
| | Prothrombin Time | 1 | 2000 | 34 | 0.180 |
Why?
| | Educational Status | 3 | 2022 | 408 | 0.180 |
Why?
| | Cholangitis, Sclerosing | 3 | 2009 | 66 | 0.180 |
Why?
| | Diagnostic Imaging | 2 | 2013 | 278 | 0.180 |
Why?
| | Recurrence | 9 | 2011 | 925 | 0.180 |
Why?
| | Analgesia, Epidural | 1 | 2000 | 20 | 0.180 |
Why?
| | Bupivacaine | 1 | 2000 | 31 | 0.180 |
Why?
| | Reperfusion | 1 | 2020 | 35 | 0.180 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 160 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 209 | 0.170 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2020 | 8 | 0.170 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 37 | 0.170 |
Why?
| | Thymidine Phosphorylase | 1 | 2020 | 12 | 0.170 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 63 | 0.170 |
Why?
| | Anesthetics, Local | 1 | 2000 | 81 | 0.170 |
Why?
| | Reproducibility of Results | 4 | 2012 | 2764 | 0.170 |
Why?
| | Choline | 4 | 1989 | 106 | 0.170 |
Why?
| | Cholestasis | 1 | 2023 | 225 | 0.170 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 246 | 0.170 |
Why?
| | Policy | 1 | 2021 | 137 | 0.170 |
Why?
| | Case-Control Studies | 4 | 2022 | 3003 | 0.170 |
Why?
| | Prognosis | 7 | 2023 | 3315 | 0.160 |
Why?
| | Nephrectomy | 1 | 2020 | 149 | 0.160 |
Why?
| | Viremia | 1 | 2020 | 122 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 1875 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2020 | 91 | 0.160 |
Why?
| | Risk | 3 | 2016 | 810 | 0.150 |
Why?
| | Catheterization | 2 | 2023 | 158 | 0.150 |
Why?
| | Sex Factors | 2 | 2017 | 1706 | 0.150 |
Why?
| | Age Distribution | 2 | 2011 | 341 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 427 | 0.150 |
Why?
| | Amyloid Neuropathies | 1 | 1998 | 1 | 0.150 |
Why?
| | Prevalence | 3 | 2023 | 2247 | 0.150 |
Why?
| | Obesity, Morbid | 2 | 2020 | 197 | 0.150 |
Why?
| | Telomerase | 1 | 2020 | 205 | 0.150 |
Why?
| | Resuscitation | 1 | 2020 | 221 | 0.150 |
Why?
| | Biliary Atresia | 1 | 2020 | 185 | 0.150 |
Why?
| | Premature Birth | 1 | 2021 | 275 | 0.150 |
Why?
| | Bile Duct Diseases | 1 | 2017 | 15 | 0.150 |
Why?
| | Phlebography | 1 | 2017 | 35 | 0.150 |
Why?
| | Social Determinants of Health | 1 | 2020 | 136 | 0.150 |
Why?
| | Bariatric Surgery | 1 | 2020 | 160 | 0.140 |
Why?
| | Reoperation | 6 | 2017 | 513 | 0.140 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 4595 | 0.140 |
Why?
| | Drug Overdose | 1 | 2021 | 292 | 0.140 |
Why?
| | Incidental Findings | 1 | 2017 | 70 | 0.140 |
Why?
| | Child | 7 | 2022 | 18400 | 0.140 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 75 | 0.140 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 104 | 0.140 |
Why?
| | Incidence | 5 | 2020 | 2314 | 0.140 |
Why?
| | Disease Progression | 4 | 2019 | 2371 | 0.140 |
Why?
| | Cause of Death | 2 | 2021 | 362 | 0.130 |
Why?
| | Perioperative Care | 1 | 2017 | 126 | 0.130 |
Why?
| | Iron | 1 | 2017 | 232 | 0.130 |
Why?
| | Cohort Studies | 8 | 2021 | 4883 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 721 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2017 | 127 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1204 | 0.130 |
Why?
| | Postoperative Care | 1 | 2017 | 223 | 0.130 |
Why?
| | Parents | 2 | 2020 | 1181 | 0.130 |
Why?
| | Postoperative Period | 4 | 2020 | 288 | 0.120 |
Why?
| | Morbidity | 2 | 2013 | 277 | 0.120 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 76 | 0.120 |
Why?
| | Monitoring, Physiologic | 2 | 1994 | 248 | 0.120 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 45 | 0.120 |
Why?
| | Cadaver | 3 | 2015 | 298 | 0.120 |
Why?
| | Costs and Cost Analysis | 2 | 2005 | 196 | 0.120 |
Why?
| | Organ Size | 2 | 2012 | 434 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 413 | 0.120 |
Why?
| | Mitochondria | 1 | 2020 | 744 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 611 | 0.120 |
Why?
| | Antilymphocyte Serum | 1 | 2014 | 60 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1447 | 0.110 |
Why?
| | Withholding Treatment | 1 | 2014 | 66 | 0.110 |
Why?
| | Steroids | 1 | 2014 | 143 | 0.110 |
Why?
| | Choline Deficiency | 3 | 1991 | 11 | 0.110 |
Why?
| | Immunophenotyping | 1 | 2014 | 274 | 0.110 |
Why?
| | Anticoagulants | 1 | 2017 | 547 | 0.110 |
Why?
| | Splenorenal Shunt, Surgical | 2 | 2006 | 3 | 0.110 |
Why?
| | Data Collection | 2 | 2013 | 618 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2015 | 376 | 0.100 |
Why?
| | Physician Executives | 1 | 2013 | 33 | 0.100 |
Why?
| | Anesthesiology | 1 | 2013 | 35 | 0.100 |
Why?
| | Thoracic Injuries | 1 | 1993 | 54 | 0.100 |
Why?
| | Catheterization, Central Venous | 1 | 1994 | 83 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1257 | 0.100 |
Why?
| | Mental Health | 1 | 2018 | 559 | 0.100 |
Why?
| | Personnel Selection | 1 | 2013 | 62 | 0.100 |
Why?
| | Therapeutic Equipoise | 1 | 2011 | 2 | 0.100 |
Why?
| | Catheter Ablation | 1 | 2015 | 287 | 0.100 |
Why?
| | Liver Function Tests | 2 | 2020 | 103 | 0.100 |
Why?
| | Body Mass Index | 1 | 2019 | 1957 | 0.090 |
Why?
| | Anastomosis, Surgical | 1 | 2011 | 135 | 0.090 |
Why?
| | Religion | 1 | 2011 | 64 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2011 | 813 | 0.090 |
Why?
| | Family Relations | 1 | 2011 | 85 | 0.090 |
Why?
| | Observer Variation | 1 | 2011 | 298 | 0.090 |
Why?
| | Health Status Indicators | 1 | 2011 | 155 | 0.090 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 25 | 0.090 |
Why?
| | Critical Illness | 1 | 2015 | 640 | 0.090 |
Why?
| | Wounds, Nonpenetrating | 1 | 1993 | 249 | 0.090 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 24 | 0.090 |
Why?
| | Specialties, Surgical | 1 | 2011 | 67 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3338 | 0.080 |
Why?
| | Hypertension, Portal | 1 | 2010 | 60 | 0.080 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 207 | 0.080 |
Why?
| | Models, Biological | 2 | 2006 | 1611 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1078 | 0.080 |
Why?
| | North America | 2 | 2023 | 255 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 768 | 0.080 |
Why?
| | S-Adenosylmethionine | 1 | 1989 | 54 | 0.080 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2009 | 48 | 0.080 |
Why?
| | Life Expectancy | 1 | 2009 | 46 | 0.080 |
Why?
| | Rats, Inbred Strains | 7 | 1991 | 360 | 0.080 |
Why?
| | Methionine | 1 | 1989 | 144 | 0.080 |
Why?
| | General Surgery | 1 | 2010 | 125 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 493 | 0.080 |
Why?
| | Ventilator Weaning | 1 | 2008 | 33 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2010 | 241 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 1994 | 1024 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 695 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 3 | 2006 | 27 | 0.070 |
Why?
| | Lithium | 1 | 1988 | 36 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 613 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2011 | 766 | 0.070 |
Why?
| | Heart Failure | 1 | 2020 | 1958 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 660 | 0.070 |
Why?
| | Animals | 12 | 2023 | 31565 | 0.070 |
Why?
| | Hypotension | 1 | 2008 | 115 | 0.070 |
Why?
| | Prealbumin | 1 | 2006 | 22 | 0.070 |
Why?
| | Parenteral Nutrition, Total | 2 | 2003 | 27 | 0.070 |
Why?
| | Survival Analysis | 4 | 2015 | 1206 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1162 | 0.070 |
Why?
| | Demography | 1 | 2007 | 258 | 0.060 |
Why?
| | Safety | 1 | 2008 | 298 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 30 | 0.060 |
Why?
| | Mice | 4 | 2023 | 14841 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 101 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2022 | 2698 | 0.060 |
Why?
| | Transplantation | 1 | 2005 | 23 | 0.060 |
Why?
| | Algorithms | 2 | 2011 | 1469 | 0.060 |
Why?
| | Pain | 2 | 2022 | 701 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1175 | 0.060 |
Why?
| | Employment | 1 | 2005 | 137 | 0.060 |
Why?
| | Depression | 2 | 2018 | 1133 | 0.060 |
Why?
| | Xanthomatosis | 1 | 2004 | 10 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2014 | 1735 | 0.050 |
Why?
| | Infant | 3 | 2021 | 7943 | 0.050 |
Why?
| | Granuloma | 1 | 2004 | 82 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 99 | 0.050 |
Why?
| | Bilirubin | 1 | 2023 | 88 | 0.050 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2003 | 18 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 47 | 0.050 |
Why?
| | Laboratories | 1 | 2023 | 95 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 330 | 0.050 |
Why?
| | Research | 1 | 2006 | 389 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 1695 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 79 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 75 | 0.050 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2002 | 17 | 0.050 |
Why?
| | Platelet Transfusion | 1 | 2022 | 55 | 0.050 |
Why?
| | RNA, Viral | 3 | 2013 | 565 | 0.050 |
Why?
| | Patients | 1 | 2023 | 163 | 0.050 |
Why?
| | Family | 1 | 2005 | 589 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 424 | 0.050 |
Why?
| | Hypophosphatemia | 1 | 2001 | 14 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 64 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2021 | 5038 | 0.050 |
Why?
| | Rats | 7 | 1991 | 4913 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 276 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 51 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 115 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 46 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 81 | 0.040 |
Why?
| | Preoperative Care | 1 | 2022 | 319 | 0.040 |
Why?
| | Receptors, CCR4 | 1 | 2020 | 15 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 312 | 0.040 |
Why?
| | Thymidine | 1 | 2020 | 58 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 74 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 140 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 428 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 66 | 0.040 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 23 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 233 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 326 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2001 | 684 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2023 | 375 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 219 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 554 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1736 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 336 | 0.040 |
Why?
| | Gastrectomy | 1 | 2020 | 81 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 2885 | 0.040 |
Why?
| | Hemangioma, Cavernous | 1 | 1999 | 14 | 0.040 |
Why?
| | Obesity | 2 | 2022 | 2505 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 552 | 0.040 |
Why?
| | HLA Antigens | 1 | 2020 | 220 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1360 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2005 | 2384 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 337 | 0.040 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 120 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 308 | 0.040 |
Why?
| | Anatomic Variation | 1 | 2017 | 3 | 0.040 |
Why?
| | Nervous System | 1 | 1998 | 63 | 0.040 |
Why?
| | Mammary Glands, Animal | 2 | 1988 | 117 | 0.040 |
Why?
| | Hepcidins | 1 | 2017 | 21 | 0.040 |
Why?
| | Pancreas Transplantation | 2 | 2009 | 61 | 0.040 |
Why?
| | Ferritins | 1 | 2017 | 52 | 0.040 |
Why?
| | Boston | 1 | 2017 | 76 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 492 | 0.040 |
Why?
| | Phosphatidylcholines | 2 | 1988 | 132 | 0.040 |
Why?
| | Hepatic Artery | 3 | 2003 | 49 | 0.040 |
Why?
| | Communication | 1 | 2022 | 734 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1125 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1228 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 507 | 0.030 |
Why?
| | Cardiovascular System | 1 | 1998 | 126 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2020 | 1075 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 294 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 192 | 0.030 |
Why?
| | Cross Infection | 1 | 1998 | 194 | 0.030 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 19 | 0.030 |
Why?
| | Hepatorenal Syndrome | 1 | 2015 | 14 | 0.030 |
Why?
| | Acute-On-Chronic Liver Failure | 1 | 2015 | 7 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2011 | 6306 | 0.030 |
Why?
| | Contrast Media | 2 | 2013 | 347 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 784 | 0.030 |
Why?
| | Benchmarking | 1 | 2016 | 161 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 77 | 0.030 |
Why?
| | Contraindications | 2 | 2006 | 84 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 828 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 295 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 452 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 519 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 205 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 121 | 0.030 |
Why?
| | Mesothelioma | 2 | 1985 | 31 | 0.030 |
Why?
| | Genotype | 2 | 2013 | 1757 | 0.030 |
Why?
| | Peritoneal Neoplasms | 2 | 1985 | 54 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2016 | 265 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1310 | 0.030 |
Why?
| | Equipment Failure | 1 | 1994 | 107 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1991 | 465 | 0.030 |
Why?
| | Constitution and Bylaws | 1 | 2013 | 1 | 0.030 |
Why?
| | Decision Trees | 1 | 1993 | 82 | 0.030 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 56 | 0.030 |
Why?
| | Hospitals, Low-Volume | 1 | 2013 | 22 | 0.030 |
Why?
| | Rabbits | 1 | 2014 | 733 | 0.030 |
Why?
| | Hospitals, High-Volume | 1 | 2013 | 38 | 0.030 |
Why?
| | Certification | 1 | 2013 | 84 | 0.030 |
Why?
| | Viral Envelope Proteins | 1 | 2013 | 73 | 0.030 |
Why?
| | Clinical Protocols | 1 | 1993 | 232 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1422 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 544 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 474 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 843 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 710 | 0.020 |
Why?
| | Patient Readmission | 1 | 2016 | 607 | 0.020 |
Why?
| | Documentation | 1 | 2013 | 166 | 0.020 |
Why?
| | Pregnancy | 2 | 2021 | 5499 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 541 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 1993 | 222 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 1993 | 669 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 919 | 0.020 |
Why?
| | Education | 1 | 2011 | 93 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 990 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1836 | 0.020 |
Why?
| | Biological Transport | 2 | 1988 | 374 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 291 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 1998 | 898 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1993 | 286 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2004 | 1331 | 0.020 |
Why?
| | Workload | 1 | 2011 | 131 | 0.020 |
Why?
| | Folic Acid | 1 | 1991 | 161 | 0.020 |
Why?
| | Methotrexate | 1 | 1991 | 227 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2010 | 69 | 0.020 |
Why?
| | Cholagogues and Choleretics | 1 | 2009 | 8 | 0.020 |
Why?
| | Ursodeoxycholic Acid | 1 | 2009 | 20 | 0.020 |
Why?
| | Brain Death | 1 | 2009 | 30 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 366 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1989 | 121 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 637 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3039 | 0.020 |
Why?
| | Blood Glucose | 1 | 1998 | 1827 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 489 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 949 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1656 | 0.020 |
Why?
| | Phosphatidylethanolamines | 1 | 1988 | 66 | 0.020 |
Why?
| | Life Style | 1 | 2011 | 428 | 0.020 |
Why?
| | Health Policy | 1 | 2011 | 330 | 0.020 |
Why?
| | Methyltransferases | 1 | 1988 | 61 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 229 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2011 | 405 | 0.020 |
Why?
| | Gastroenterology | 1 | 2010 | 159 | 0.020 |
Why?
| | Breast | 1 | 1988 | 138 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 9114 | 0.020 |
Why?
| | Needs Assessment | 1 | 2010 | 315 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 513 | 0.020 |
Why?
| | Betaine | 1 | 1988 | 63 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3397 | 0.020 |
Why?
| | Selenium | 1 | 1987 | 31 | 0.020 |
Why?
| | Selenium Compounds | 1 | 1987 | 21 | 0.020 |
Why?
| | Fellowships and Scholarships | 1 | 2010 | 224 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 1987 | 98 | 0.020 |
Why?
| | Clinical Competence | 1 | 2013 | 882 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2008 | 214 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4402 | 0.020 |
Why?
| | Survivors | 1 | 2009 | 412 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 445 | 0.020 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.020 |
Why?
| | Etoposide | 1 | 1984 | 149 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1984 | 158 | 0.010 |
Why?
| | Lung Transplantation | 1 | 2006 | 244 | 0.010 |
Why?
| | Tissue Adhesions | 1 | 2004 | 26 | 0.010 |
Why?
| | Curriculum | 1 | 2010 | 813 | 0.010 |
Why?
| | Internship and Residency | 1 | 2013 | 920 | 0.010 |
Why?
| | Lacerations | 1 | 2004 | 27 | 0.010 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2004 | 81 | 0.010 |
Why?
| | Abdomen | 1 | 2004 | 99 | 0.010 |
Why?
| | Erythrocytes | 1 | 1988 | 568 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1988 | 532 | 0.010 |
Why?
| | Inflammation | 1 | 1993 | 2464 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 2004 | 120 | 0.010 |
Why?
| | Angiography | 1 | 2003 | 176 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 2002 | 9 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1531 | 0.010 |
Why?
| | Azathioprine | 1 | 2001 | 49 | 0.010 |
Why?
| | Spleen | 1 | 2003 | 485 | 0.010 |
Why?
| | Ischemia | 1 | 2003 | 361 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 221 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 381 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2003 | 284 | 0.010 |
Why?
| | APACHE | 1 | 1998 | 58 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2001 | 511 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 206 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 208 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1690 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 1356 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1984 | 2159 | 0.010 |
Why?
| | Combined Modality Therapy | 2 | 1985 | 1117 | 0.010 |
Why?
| | Pteroylpolyglutamic Acids | 1 | 1991 | 1 | 0.010 |
Why?
| | Tetrahydrofolates | 1 | 1991 | 11 | 0.010 |
Why?
| | Phosphatidylethanolamine N-Methyltransferase | 1 | 1988 | 8 | 0.000 |
Why?
| | Hemicholinium 3 | 1 | 1988 | 1 | 0.000 |
Why?
| | Dinitrophenols | 1 | 1988 | 7 | 0.000 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 8 | 0.000 |
Why?
| | Ouabain | 1 | 1988 | 15 | 0.000 |
Why?
| | Osmolar Concentration | 1 | 1988 | 169 | 0.000 |
Why?
| | Methylation | 1 | 1988 | 208 | 0.000 |
Why?
| | Selenium Radioisotopes | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenious Acid | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenomethionine | 1 | 1987 | 3 | 0.000 |
Why?
| | Lactation | 1 | 1988 | 149 | 0.000 |
Why?
| | Milk | 1 | 1988 | 123 | 0.000 |
Why?
| | Epithelium | 1 | 1988 | 295 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1988 | 1003 | 0.000 |
Why?
| | Kinetics | 1 | 1988 | 1547 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1984 | 77 | 0.000 |
Why?
| | Asbestos | 1 | 1983 | 19 | 0.000 |
Why?
| | Laparotomy | 1 | 1983 | 101 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1988 | 946 | 0.000 |
Why?
| | Palliative Care | 1 | 1985 | 641 | 0.000 |
Why?
|
|
Pomfret's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|